Herbal Preparations of Medical Cannabis: A Vademecum for Prescribing Doctors
Abstract
:1. Introduction
2. Methodology
3. Herbal Preparations of Medicinal Cannabis
3.1. Cannabis Flowering Tops Decoction Preparation
3.2. Cannabis Flowering Tops Oil Extract Preparation
3.3. Inhalation of Cannabis Flowering Tops with Vaporizing Systems
4. Vademecum for Prescribing Doctors
4.1. Medical Use and Physician’s Recommendations
4.2. Dosages and Titration Strategies
- Anorexia: THC > CBD;
- Nausea and vomiting: THC > CBD;
- Insomnia: THC ≅ CBD;
- Depression: THC ≅ CBD;
- Pain: THC ≅ CBD;
- Multiple sclerosis: THC ≅ CBD;
- Tourette syndrome: THC ≅ CBD;
- Alzheimer’s disease: THC ≅ CBD;
- Anxiety: THC < CBD;
- Colitis: THC < CBD;
- Epilepsy: THC < CBD;
- Psychosis: THC < CBD;
- Parkinson’s disease: THC < CBD.
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- European Monitoring Center for Drugs and Drug Addiction (EMCDDA). Medical Use of Cannabis and Cannabinoids: Questions and Answers for Policymaking 2018. Available online: http://www.emcdda.europa.eu/system/files/publications/10171/20185584_TD0618186ENN_PDF.pdf (accessed on 12 March 2020).
- Cáceres Guido, P.; Riva, N.; Calle, G.; Dell’Orso, M.; Gatto, M.; Sberna, N.; Schaiquevich, P. Medicinal cannabis in Latin America: History, current state of regulation, and the role of the pharmacist in a new clinical experience with cannabidiol oil. J. Am. Pharm. Assoc. 2019, 60, 212–215. [Google Scholar] [CrossRef]
- Fraguas-Sánchez, A.I.; Torres-Suárez, A.I. Medical Use of Cannabinoids. Drugs 2018, 78, 1665–1703. [Google Scholar] [CrossRef] [PubMed]
- Zuardi, A.W. History of cannabis as a medicine: A review. Rev. Bras. Psiquiatr. 2006, 28, 153–157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bonini, S.A.; Premoli, M.; Tambaro, S.; Kumar, A.; Maccarinelli, G.; Memo, M.; Mastinu, A. Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. J. Ethnopharmacol. 2018, 227, 300–315. [Google Scholar] [CrossRef]
- Brand, E.J.; Zhao, Z. Cannabis in Chinese medicine: Are some traditional indications referenced in ancient literature related to cannabinoids? Front. Pharmacol. 2017, 8, 1–11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pisanti, S.; Bifulco, M. Modern History of Medical Cannabis: From Widespread Use to Prohibitionism and Back. Trends Pharmacol. Sci. 2017, 38, 195–198. [Google Scholar] [CrossRef]
- U.S. Treasury Department; Bureau of Narcotics. The Marihuana Tax Act of Aug. 2, 1937, Public Law 238, 75th Congress. n.d. Available online: http://www.druglibrary.org/schaffer/hemp/taxact/mjtaxact.htm (accessed on 14 March 2020).
- Mikuriya, T.H. Marijuana in Medicine. Calif. Med. 1969, 110, 34–40. [Google Scholar]
- United Nations. Single Conference on Narcotic Drugs 1961. Available online: https://www.unodc.org/pdf/convention_1961_en.pdf (accessed on 14 March 2020).
- Mechoulam, R.; Shvo, Y.; Hashish, -I. The structure of Cannabidiol. Tetrahedron 1963, 19, 2073–2078. [Google Scholar] [CrossRef]
- Mechoulam, R.; Gaoni, Y. A Total Synthesis of dl-Δ1-Tetrahydrocannabinol, the Active Constituent of Hashish. J. Am. Chem. Soc. 1965, 87, 3273–3275. [Google Scholar] [CrossRef]
- Mechoulam, R.; Varconi, H.; Ben-Zvi, Z.; Edery, H.; Grunfeld, Y. Synthesis and biological activity of five tetrahydrocannabinol metabolites. J. Am. Chem. Soc. 1972, 94, 7930–7931. [Google Scholar] [CrossRef]
- Mechoulam, R.; Braun, P.; Gaoni, Y. Syntheses of Δ1-Tetrahydrocannabinol and Related Cannabinoids. J. Am. Chem. Soc. 1972, 94, 6159–6165. [Google Scholar] [CrossRef] [PubMed]
- United Nations. Convention on Psychotropic Substances 1971. Available online: https://www.unodc.org/pdf/convention_1971_en.pdf (accessed on 15 March 2020).
- US Food and Drug Administration (FDA). Highlights of Prescribing Information for Marinol® n.d. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf (accessed on 16 March 2020).
- US Food and Drug Administration (FDA). Nabilone Approval Letter n.d. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf (accessed on 16 March 2020).
- Burns, T.L.; Ineck, J.R. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann. Pharmacother. 2006, 40, 251–260. [Google Scholar] [CrossRef] [PubMed]
- Croxford, J.L. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs CNS Drugs 2003, 17, 179–202. [Google Scholar] [CrossRef] [PubMed]
- Manzanares, J.; Julian, M.D.; Carrascosa, A. Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes. Curr. Neuropharmacol. 2006, 4, 239–257. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pertwee, R.G. Cannabinoids and multiple sclerosis. Pharmacol. Ther. 2002, 95, 165–174. [Google Scholar] [CrossRef]
- Cannabis-based medicines-GW pharmaceuticals: High CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC: CBD. Drugs R&D 2003, 4, 306–309. [CrossRef]
- Cortesi, M.; Fusar-Poli, P. Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy. Med. Hypotheses 2007, 68, 920–921. [Google Scholar] [CrossRef]
- Grant, I.; Cahn, B.R. Cannabis and endocannabinoid modulators: Therapeutic promises and challenges. Clin. Neurosci. Res. 2005, 5, 185–199. [Google Scholar] [CrossRef] [Green Version]
- Muller-Vahl, K.R. Cannabinoids reduce symptoms of Tourette’s syndrome. Expert Opin. Pharmacother. 2003, 4, 1717–1725. [Google Scholar] [CrossRef]
- Müller-Vahl, K.R.; Kolbe, H.; Schneider, U.; Emrich, H.M. Cannabis in Movement Disorders. Complement. Med. Res. 1999, 6, 23–27. [Google Scholar] [CrossRef]
- National Archives. Federal Register Statement of Principles on Industrial Hemp n.d. Available online: https://www.federalregister.gov/documents/2016/08/12/2016-19146/statement-of-principles-on-industrial-hemp (accessed on 10 March 2020).
- The European Parliament and the Council of the European Union. Regulation (EU) No 1307/2013 of 17 December 2013 n.d. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32013R1307&from=EN (accessed on 11 March 2020).
- Hudak, J. The Farm Bill, Hemp Legalization and the Status of CBD: An Explainer. Brookings Inst 2018. Available online: https://www.brookings.edu/blog/fixgov/2018/12/14/the-farm-bill-hemp-and-cbd-explainer/ (accessed on 5 March 2020).
- Giroud, C.; De Cesare, M.; Berthet, A.; Varlet, V.; Concha-Lozano, N.; Favrat, B. E-cigarettes: A review of new trends in cannabis use. Int. J. Environ. Res. Public Health 2015, 12, 9988–10008. [Google Scholar] [CrossRef] [PubMed]
- European Monitoring Center for Drugs and Drug addiction (EMCDDA). Developments in the European Cannabis Market 2019:1–19. Available online: http://www.emcdda.europa.eu/system/files/publications/11391/TDAU19001ENN.pdf (accessed on 5 March 2020).
- Pichini, S.; Mannocchi, G.; Gottardi, M.; Pérez-Acevedo, A.P.; Poyatos, L.; Papaseit, E.; Pérez-Mañá, C.; Farré, M.; Pacifici, R.; Busardò, F.P. Fast and sensitive UHPLC-MS/MS analysis of cannabinoids and their acid precursors in pharmaceutical preparations of medical cannabis and their metabolites in conventional and non-conventional biological matrices of treated individual. Talanta 2020, 209, 120537. [Google Scholar] [CrossRef] [PubMed]
- Verhoeckx, K.C.M.; Korthout, H.A.A.J.; Van Meeteren-Kreikamp, A.P.; Ehlert, K.A.; Wang, M.; Van Der Greef, J.; Rodenburg, R.J.; Witkamp, R. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int. Immunopharmacol. 2006, 6, 656–665. [Google Scholar] [CrossRef] [PubMed]
- Pacifici, R.; Marchei, E.; Salvatore, F.; Guandalini, L.; Busardò, F.P.; Pichini, S. Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry. Clin. Chem. Lab. Med. 2017, 55, 1555–1563. [Google Scholar] [CrossRef] [PubMed]
- Russo, E.B. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br. J. Pharmacol. 2011, 163, 1344–1364. [Google Scholar] [CrossRef]
- Russo, E.B.; Marcu, J. Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads. Adv. Pharmacol. 2017, 80, 67–134. [Google Scholar] [CrossRef]
- Namdar, D.; Voet, H.; Ajjampura, V.; Nadarajan, S.; Mayzlish-Gati, E.; Mazuz, M.; Shalev, N.; Koltai, H. Terpenoids and phytocannabinoids co-produced in cannabis sativa strains show specific interaction for ell cytotoxic activity. Molecules 2019, 24, 3031. [Google Scholar] [CrossRef] [Green Version]
- Pacifici, R.; Marchei, E.; Salvatore, F.; Guandalini, L.; Busardò, F.P.; Pichini, S. Evaluation of long-term stability of cannabinoids in standardized preparations of cannabis flowering tops and cannabis oil by ultra-high-performance liquid chromatography tandem mass spectrometry. Clin. Chem. Lab. Med. 2018, 56, 94–96. [Google Scholar] [CrossRef]
- World Health Organization (WHO). Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants n.d. Available online: https://apps.who.int/medicinedocs/en/d/Js4928e/ (accessed on 17 March 2020).
- Pacifici, R.; Marchei, E.; Salvatore, F.; Guandalini, L.; Busardò, F.P.; Pichini, S. Stability of cannabinoids in cannabis FM1 flowering tops and oil preparation evaluated by ultra-high performance liquid chromatography tandem mass spectrometry. Clin. Chem. Lab. Med. 2019, 57, E165–E168. [Google Scholar] [CrossRef]
- The Office of Medicinal Cannabis. Dutch Patients and Businesses | Import and Export. Off Med Cannabis n.d. Available online: https://english.cannabisbureau.nl/import-and-export (accessed on 5 March 2020).
- The Office of Medicinal Cannabis. Types of Medicinal Cannabis | Medicinal Cannabis | The Office of Medicinal Cannabis n.d. Available online: https://english.cannabisbureau.nl/medicinal-cannabis/types-of-medicinal-cannabis (accessed on 17 March 2020).
- Ministero Della Salute E Ministero Della Difesa. Accordo 18 Settembre 2014 n.d. Available online: http://www.salute.gov.it/imgs/C_17_notizie_1737_listaFile_itemName_0_file.pdf (accessed on 7 March 2020).
- Ministero Della Salute. Decreto 9 Novembre 2015, Funzioni Di Organismo Statale Per La Cannabis Previsto Dagli Articoli 23 E 28 Della Convenzione Unica Sugli Stupefacenti Del 1961, Come Modificata Nel 1972. (15A08888) (GU Serie Generale n.279 del 30-11-2015). Gazz Uff Della Repubb Ital n.d. Available online: https://www.epicentro.iss.it/cannabis-uso-medico/pdf/Decreto uso medico Cannabis(GU 30.11.2015).pdf (accessed on 7 March 2020).
- Bedrocan –Products-Services n.d. Available online: https://bedrocan.com/products-services/healthcare/prescribing-cannabis/ (accessed on 18 March 2020).
- Canadian Medical Marijuana Producer | Aurora Cannabis n.d. Available online: https://www.auroramj.com/ (accessed on 18 March 2020).
- Available Cannabis Strains –Spectrum Therapeutics n.d. Available online: https://shop.spectrumtherapeutics.com/collections/available (accessed on 18 March 2020).
- Hazekamp, A.; Bastola, K.; Rashidi, H.; Bender, J.; Verpoorte, R. Cannabis tea revisited: A systematic evaluation of the cannabinoid composition of cannabis tea. J. Ethnopharmacol. 2007, 113, 85–90. [Google Scholar] [CrossRef]
- European Monitoring Center for Drugs and Drug Addiction (EMCDDA). Cannabis Legislation in Europe 2017. Available online: http://www.emcdda.europa.eu/system/files/publications/4135/TD0217210ENN.pdf (accessed on 5 March 2020).
- Romano, L.L.; Hazekamp, A. Cannabis Oil: Chemical evaluation of an upcoming cannabis-based medicine. Cannabinoids 2013, 1, 1–11. [Google Scholar]
- Medical Jane. Medical Marijuana Strain Reviews n.d. Available online: https://www.medicaljane.com/category/strains/ (accessed on 22 March 2020).
- Volcano® Vaporization System n.d. Available online: https://www.vapormed.com/media/pdf/Volcano_Medic_Vaporizer_Manual_Instructions.pdf (accessed on 22 March 2020).
- He, T.; Oks, M.; Esposito, M.; Steinberg, H.; Makaryus, M. “Tree-in-Bloom”: Severe Acute Lung Injury Induced by Vaping Cannabis Oil. Ann. Am. Thorac. Soc. 2017, 14, 468–470. [Google Scholar] [CrossRef] [PubMed]
- Perrine, C.G.; Pickens, C.M.; Boehmer, T.K.; King, B.A.; Jones, C.M.; DeSisto, C.L.; Duca, L.M.; Lekiachvili, A.; Kenemer, B.; Shamout, M.; et al. Characteristics of a Multistate Outbreak of Lung Injury Associated with E-cigarette Use, or Vaping-United States, 2019. MMWR. Morb. Mortal. Wkly. Rep. 2019, 68, 860–864. [Google Scholar] [CrossRef] [PubMed]
- U.S. Department of Justice. Title 21 United States Code (USC) Controlled Substances Act, Subchapter I Control and Enforcement, Part A Introductory Provisions, §802. Definitions n.d. Available online: https://www.deadiversion.usdoj.gov/21cfr/21usc/802.htm (accessed on 28 October 2019).
- Mead, A. Legal and regulatory issues governing cannabis and cannabis-derived products in the United States. Front. Plant Sci. 2019, 10, 1–10. [Google Scholar] [CrossRef]
- VanDolah, H.J.; Bauer, B.A.; Mauck, K.F. Clinicians’ Guide to Cannabidiol and Hemp Oils. Mayo Clin. Proc. 2019, 94, 1840–1851. [Google Scholar] [CrossRef] [Green Version]
- Ziemiański, D.; Capler, R.; Tekanoff, R.; Lacasse, A.; Luconi, F.; Ware, M.A. Cannabis in medicine: A national educational needs assessment among Canadian physicians Career choice, professional education and development. BMC Med. Educ. 2015, 15, 1–7. [Google Scholar] [CrossRef] [Green Version]
- Bifulco, M.; Pisanti, S. Medicinal use of cannabis in Europe. EMBO Rep. 2015, 16, 130–132. [Google Scholar] [CrossRef] [Green Version]
- Romero-Sandoval, E.A.; Fincham, J.E.; Kolano, A.L.; Sharpe, B.N.; Alvarado-Vázquez, P.A. Cannabis for Chronic Pain: Challenges and Considerations. Pharmacotherapy 2018, 38, 651–662. [Google Scholar] [CrossRef]
- Zendulka, O.; Dovrtelova, G.; Nosková, K.; Turjap, M.; Sulcova, A.; Hanuš, L.; Juřica, J. Cannabinoids and Cytochrome P450 Interactions. Curr. Drug Metab. 2016, 17, 206–226. [Google Scholar] [CrossRef]
- Galaj, E.; Xi, Z.-X. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. CNS Drugs 2019, 33, 1001–1030. [Google Scholar] [CrossRef]
- McPartland, J.M.; Guy, G.W.; Di Marzo, V. Care and feeding of the endocannabinoid system: A systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS ONE 2014, 9. [Google Scholar] [CrossRef] [PubMed]
- Pisanti, S.; Malfitano, A.M.; Ciaglia, E.; Lamberti, A.; Ranieri, R.; Cuomo, G.; Abate, M.; Faggiana, G.; Proto, M.C.; Fiore, D.; et al. State of the art and new challenges for therapeutic applications. Pharmacol. Ther. 2017, 175, 133–150. [Google Scholar] [CrossRef] [PubMed]
- Hohmann, A.G. Spinal and peripheral mechanisms of cannabinoid antinociception: Behavioral, neurophysiological and neuroanatomical perspectives. Chem. Phys. Lipids 2002, 121, 173–190. [Google Scholar] [CrossRef]
- Walker, J.M.; Hohmann, A.G.; Martin, W.J.; Strangman, N.M.; Huang, S.M.; Tsou, K. The neurobiology of cannabinoid analgesia. Life Sci. 1999, 65, 665–673. [Google Scholar] [CrossRef]
- Lötsch, J.; Weyer-Menkhoff, I.; Tegeder, I. Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings. Eur. J. Pain 2017, 22, 471–484. [Google Scholar] [CrossRef]
- Hill, K.P.; Palastro, M.D.; Johnson, B.; Ditre, J.W. Cannabis and Pain: A Clinical Review. Cannabis Cannabinoid Res. 2017, 2, 96–104. [Google Scholar] [CrossRef] [Green Version]
- Taskar, P.; Patil, A.; Lakhani, P.; Ashour, E.; Gul, W.; ElSohly, M.A.; Murphy, B.; Majumdar, S. Δ9-Tetrahydrocannabinol Derivative-Loaded Nanoformulation Lowers Intraocular Pressure in Normotensive Rabbits. Transl. Vis. Sci. Technol. 2019, 8. [Google Scholar] [CrossRef] [Green Version]
- Calapai, G.; Mannucci, C.; Chinou, I.; Cardia, L.; Calapai, F.; Sorbara, E.E.; Firenzuoli, B.; Ricca, V.; Gensini, G.F.; Firenzuoli, F. Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry. Evidence-Based Complement. Altern. Med. 2019, 2019, 1–11. [Google Scholar] [CrossRef] [Green Version]
- Abrams, D.I. The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. Eur. J. Intern. Med. 2018, 49, 7–11. [Google Scholar] [CrossRef]
- Kleckner, A.S.; Kleckner, I.R.; Kamen, C.S.; Tejani, M.A.; Janelsins, M.C.; Morrow, G.R.; Peppone, L.J. Opportunities for cannabis in supportive care in cancer. Ther. Adv. Med Oncol. 2019, 11, 1–29. [Google Scholar] [CrossRef] [Green Version]
- Gorter, R.W. Cancer Cachexia and Cannabinoids. Complement. Med. Res. 1999, 6, 21–22. [Google Scholar] [CrossRef] [PubMed]
- Farokhnia, M.; McDiarmid, G.R.; Newmeyer, M.N.; Munjal, V.; Abulseoud, O.A.; Huestis, M.A.; Leggio, L. Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: A randomized, double-blind, placebo-controlled, human laboratory study. Transl. Psychiatry 2020, 10. [Google Scholar] [CrossRef] [Green Version]
- Pellati, F.; Borgonetti, V.; Brighenti, V.; Biagi, M.; Benvenuti, S.; Corsi, L. Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. BioMed Res. Int. 2018, 2018, 1–15. [Google Scholar] [CrossRef] [Green Version]
- Nadal, X.; Del Río, C.; Casano, S.; Palomares, B.; Ferreiro-Vera, C.; Navarrete, C.; Sánchez-Carnerero, C.; Cantarero, I.; Bellido, M.L.; Meyer, S.; et al. Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity. Br. J. Pharmacol. 2017, 174, 4263–4276. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Leussink, V.I.; Husseini, L.; Warnke, C.; Broussalis, E.; Hartung, H.P.; Kieseier, B.C. Symptomatic therapy in multiple sclerosis: The role of cannabinoids in treating spasticity. Ther. Adv. Neurol. Disord. 2012, 5, 255–266. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Russo, E.B. Cannabis therapeutics and the future of neurology. Front. Integr. Neurosci. 2018, 12. [Google Scholar] [CrossRef] [PubMed]
- Mannucci, C.; Navarra, M.; Calapai, F.; Spagnolo, E.V.; Busardò, F.P.; Cas, R.D.; Ippolito, F.M.; Calapai, G. Neurological Aspects of Medical Use of Cannabidiol. CNS Neurol. Disord. Drug Targets 2017, 16, 541–553. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bakas, T.; Van Nieuwenhuijzen, P.S.; Devenish, S.; McGregor, I.S.; Arnold, J.; Chebib, M. The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors. Pharmacol. Res. 2017, 119, 358–370. [Google Scholar] [CrossRef]
- Ford, T.C.; Hayley, A.C.; Downey, L.A.; Parrott, A.C. Cannabis: An overview of its adverse acute and chronic effects and its implications. Curr. Drug Abus. Rev. 2017, 10, 6–18. [Google Scholar] [CrossRef] [Green Version]
- Nutt, D.J.; Lingford-Hughes, A.; Erritzoe, D.; Stokes, P.R.A. The dopamine theory of addiction: 40 years of highs and lows. Nat. Rev. Neurosci. 2015, 16, 305–312. [Google Scholar] [CrossRef] [Green Version]
- Crescioli, G.; Vannacci, A.; Bettiol, A.; Menniti-Ippolito, F.; Da Cas, R.; Parrilli, M.; Del Lungo, M.; Gallo, E.; Mugelli, A.; Maggini, V.; et al. Adverse events following cannabis for medical use in Tuscany: An analysis of the Italian Phytovigilance database. Br. J. Clin. Pharmacol. 2020, 86, 106–120. [Google Scholar] [CrossRef] [PubMed]
- Istituto Superiore Di Sanità (ISS). ISSalute-Cannabis E Cannabinoidi: Effetti e Rischi Per La Salute n.d. Available online: https://www.issalute.it/index.php/la-salute-dalla-a-alla-z-menu/c/cannabis-e-cannabinoidi (accessed on 23 March 2020).
- Rudroff, T.; Sosnoff, J.J. Cannabidiol to improve mobility in people with multiple sclerosis. Front. Neurol. 2018, 9, 1–3. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wong, K.U.; Baum, C.R. Acute Cannabis Toxicity. Pediatr. Emerg. Care 2019, 35, 799–806. [Google Scholar] [CrossRef] [PubMed]
- Sistema Di Fitovigilanza. Rapporto dell’Istituto Superiore Di Sanità (ISS) Sulle Segnalazioni Da Cannabis Per Uso Medico: Ricevute 76 Segnalazioni Di Reazione Avversa. n.d. Available online: http://www.farmacovigilanza.unina2.it/index.php?option=com_content&view=article&id=805:rapporto-dell-istituto-superiore-di-sanita-iss-sulle-segnalazioni-da-cannabis-per-uso-medico-ricevute-76-segnalazioni-di-reazione-avversa&catid=72&Itemid=485&lang=en (accessed on 23 March 2020).
- Direzione Generale Dei Dispositivi Medici E Del Servizio Farmaceutico. Ministero Della Salute n.d. Available online: http://www.salute.gov.it/portale/temi/p2_4.jsp?lingua=italiano&tema=Dispositivi%2520medici%2520e%252 (accessed on 23 March 2020).
- Maida, V.; Daeninck, P.J. A user’s guide to cannabinoid therapies in oncology. Curr. Oncol. 2016, 23, 398–406. [Google Scholar] [CrossRef] [Green Version]
- Schmitz, N.; Richert, L. Pharmacists and the future of cannabis medicine. J. Am. Pharm. Assoc. 2019, 60, 207–211. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zehra, A.; Burns, J.; Liu, C.K.; Manza, P.; Wiers, C.E.; Volkow, N.D.; Wang, G.J. Cannabis Addiction and the Brain: A Review. J. Neuroimmune Pharmacol. 2018, 13, 438–453. [Google Scholar] [CrossRef] [Green Version]
- Grotenhermen, F. Pharmacokinetics and Pharmacodynamics of Cannabinoids. Clin. Pharmacokinet. 2003, 42, 327–360. [Google Scholar] [CrossRef]
- Wiesbeck, G.A.; Schuckit, M.A.; Kalmijn, J.A.; Tipp, J.E.; Bucholz, K.K.; Smith, T.L. An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction 1996, 91, 1469–1478. [Google Scholar] [CrossRef]
- Hezode, C.; Zafrani, E.S.; Roudot–Thoraval, F.; Costentin, C.; Hessami, A.; Bouvier-Alias, M.; Medkour, F.; Pawlostky, J.; Lotersztajn, S.; Mallat, A. Daily Cannabis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis C. Gastroenterology 2008, 134, 432–439. [Google Scholar] [CrossRef]
- Alsherbiny, M.A.; Li, C. Medicinal Cannabis—Potential. Drug Interact. Med. 2018, 6, 3. [Google Scholar] [CrossRef] [Green Version]
- Huestis, M.A.; Solimini, R.; Pichini, S.; Pacifici, R.; Carlier, J.; Busardò, F.P. Cannabidiol Adverse Effects and Toxicity. Curr. Neuropharmacol. 2019, 17, 1–16. [Google Scholar] [CrossRef] [PubMed]
- Eichler, M.; Spinedi, L.; Unfer-Grauwiler, S.; Bodmer, M.; Surber, C.; Luedi, M.; Drewe, J. Heat exposure of cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. Planta Med. 2012, 78, 686–691. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qian, Y.; Gurley, B.J.; Markowitz, J.S. The Potential for Pharmacokinetic Interactions between Cannabis Products and Conventional Medications. J. Clin. Psychopharmacol. 2019, 39, 462–471. [Google Scholar] [CrossRef] [PubMed]
- Taylor, L.; Crockett, J.; Tayo, B.; Morrison, G. A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects with Mild to Severe Hepatic Impairment. J. Clin. Pharmacol. 2019, 59, 1110–1119. [Google Scholar] [CrossRef]
- Carlier, J.; Huestis, M.A.; Zaami, S.; Pichini, S.; Busardò, F.P. Monitoring the effects of perinatal cannabis and synthetic cannabinoid exposure. Ther. Drug Monit. 2020, 42, 194–204. [Google Scholar] [CrossRef]
- Thomas, A.A.; Mazor, S. Unintentional Marijuana Exposure Presenting as Altered Mental Status in the Pediatric Emergency Department: A Case Series. J. Emerg. Med. 2017, 53, e119–e123. [Google Scholar] [CrossRef]
- Carter, G.T.; Weydt, P.; Kyashna-Tocha, M.; Abrams, D.I. Medicinal cannabis: Rational guidelines for dosing. IDrugs 2004, 7, 464–470. [Google Scholar]
- Rotolo, M.C.; Pellegrini, M.; Martucci, P.; Giacobbe, R.; De Palma, A.; Pacifici, R.; Pichini, S.; Busardò, F.P.; Bisconti, M. Cannabinoids determination in bronchoalveolar lavages of cannabis smokers with lung disease. Clin. Chem. Lab. Med. 2019, 57, 498–503. [Google Scholar] [CrossRef]
- Lucas, C.; Galettis, P.; Schneider, J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br. J. Clin. Pharmacol. 2018, 84, 2477–2482. [Google Scholar] [CrossRef] [Green Version]
- Huestis, M.A. Human cannabinoid pharmacokinetics. Chem. Biodivers. 2007, 4, 1770–1804. [Google Scholar] [CrossRef] [Green Version]
- International Conference on Harmonisation (ICH). All Guidelines. Available online: https://www.ich.org/page/ich-guidelines (accessed on 19 April 2020).
- Schuck, R.N.; Pacanowski, M.; Kim, S.; Madabushi, R.; Zineh, I. Use of Titration as a Therapeutic Individualization Strategy: An Analysis of Food and Drug Administration–Approved Drugs. Clin. Transl. Sci. 2019, 12, 236–239. [Google Scholar] [CrossRef] [PubMed]
- Maccallum, C.A.; Russo, E.B. Practical considerations in medical cannabis administration and dosing. Eur. J. Intern. Med. 2018, 49, 12–19. [Google Scholar] [CrossRef] [PubMed]
- Brown, D.; Watson, M.; Schloss, J. Pharmacological evidence of medicinal cannabis in oncology: A systematic review. Support. Care Cancer 2019, 27, 3195–3207. [Google Scholar] [CrossRef] [PubMed]
Producer | Variety | %THC * | %CBD * | Origin | Indications |
---|---|---|---|---|---|
THC > CBD | Chronic pain; multiple sclerosis; nausea; vomiting; loss of weight; Tourette syndrome; glaucoma; cancer; epilepsy; inflammatory bowel diseases; Parkinson’s disease; psychiatric disorders. | ||||
Bedrocan International® | Bedrocan® | ≅22 | <1 | Netherlands | |
Bedica® | ≅14 | <1 | |||
Bedrobinol® | ≅13.5 | <1 | |||
Aurora Cannabis Inc. (ACB) | Pedanios 22/1 | ≅22 | <1 | Canada | |
Spectrum Therapeutics™ | Red n°1 Flower | 20–23 (21.5 **) | <0.7 | ||
Red n°2 Flower | 17–20 (18.5 **) | <0.7 | |||
Orange Flower | 10–13 (11.5 **) | <0.7 | |||
Purple Flower | 8–11 (9.5 **) | <0.7 | |||
- | FM1 | 14.1 | 0.1 | Italy | |
THC ≅ CBD | |||||
Bedrocan Inernational® | Bediol® | ≅6.3 | ≅8 | Netherlands | |
Aurora Cannabis Inc. (ACB) | Pedanios 8/8 | ≅8 | ≅8 | Canada | |
Spectrum Therapeutics™ | Blue Flower | 6–9 (7.5 **) | 8–11 (9.5 **) | ||
Green Flower | 4–7 (5.5 **) | 7–10 (8.5 **) | |||
- | FM2 | 5.8 | 8.1 | Italy | |
THC < CBD | |||||
Bedrocan International® | Bedrolite® | <1 | ≅9 | Netherlands | |
Aurora Cannabis Inc. (ACB) | Pedanios 1/9 | <1 | ≅9 | Canada | |
Spectrum Therapeutics™ | Yellow Flower | <1 | 11–14 (12.5 **) |
Varieties | Medical Cannabis Decoction | Medical Cannabis Oil | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
50 mL | 100 mL | 500 mL | 10 Oil Drops | 20 Oil Drops | 50 Oil Drops | |||||||
mg THC | mg CBD | mg THC | mg CBD | mg THC | mg CBD | mg THC | mg CBD | mg THC | mg CBD | mg THC | mg CBD | |
THC > CBD | ||||||||||||
Bedrocan® | 1.72 | <0.30 | 3.43 | <0.60 | 17.21 | <2.30 | 4.37 | <0.20 | 8.74 | <0.40 | 21.84 | <1 |
Pedanios 22/1 | 1.72 | <0.30 | 3.43 | <0.60 | 17.21 | <2.30 | 4.37 | <0.20 | 8.74 | <0.40 | 21.84 | <1 |
Red Flower n°1 | 1.68 | <0.21 | 3.35 | <0.42 | 16.81 | <1.61 | 4.27 | <0.14 | 8.54 | <0.28 | 21.35 | <0.70 |
Red Flower n°2 | 1.44 | <0.21 | 2.87 | <0.42 | 14.47 | <1.61 | 3.67 | <0.14 | 7.34 | <0.28 | 18.36 | <0.70 |
FM1 | 1.10 | 0.03 | 2.20 | 0.06 | 11.03 | 0.23 | 2.80 | 0.02 | 5.60 | 0.04 | 14.00 | 0.10 |
Bedica® | 1.09 | <0.30 | 2.19 | <0.60 | 10.95 | <2.30 | 2.78 | <0.20 | 5.56 | <0.40 | 13.90 | <1 |
Bedrobinol® | 1.05 | <0.30 | 2.12 | <0.60 | 10.55 | <2.30 | 2.68 | <0.20 | 5.36 | <0.40 | 13.40 | <1 |
Orange Flower | 0.90 | <0.21 | 1.79 | <0.42 | 9.00 | <1.61 | 2.28 | <0.14 | 4.57 | <0.28 | 11.42 | <0.70 |
Purple Flower | 0.74 | <0.21 | 1.48 | <0.42 | 7.43 | <1.61 | 1.89 | <0.14 | 3.77 | <0.28 | 9.43 | <0.70 |
THC ≅ CBD | ||||||||||||
Pedanios 8/8 | 0.66 | 1.94 | 1.32 | 3.86 | 6.66 | 19.27 | 1.59 | 2.28 | 3.17 | 4.56 | 7.93 | 11.41 |
Blue Flower | 0.62 | 2.30 | 1.24 | 4.59 | 6.25 | 22.88 | 1.49 | 2.71 | 2.97 | 5.42 | 7.44 | 13.55 |
Bediol® | 0.52 | 1.94 | 1.04 | 3.86 | 5.25 | 19.27 | 1.25 | 2.28 | 2.50 | 4.56 | 6.25 | 11.41 |
FM2 | 0.48 | 1.96 | 0.96 | 3.91 | 4.83 | 19.51 | 1.15 | 2.31 | 2.30 | 4.62 | 5.75 | 11.55 |
Green Flower | 0.46 | 2.06 | 0.91 | 4.10 | 4.58 | 20.47 | 1.10 | 2.42 | 2.18 | 4.85 | 5.45 | 12.12 |
THC < CBD | ||||||||||||
Bedrolite® | <0.08 | 2.18 | <0.17 | 4.34 | <0.83 | 21.68 | <0.20 | 2.57 | <0.40 | 5.13 | <1 | 12.83 |
Pedanios 1/9 | <0.08 | 2.18 | <0.17 | 4.34 | <0.83 | 21.68 | <0.20 | 2.57 | <0.40 | 5.13 | <1 | 12.83 |
Yellow Flower | <0.08 | 3.02 | <0.17 | 6.03 | <0.83 | 30.11 | <0.20 | 3.56 | <0.40 | 7.13 | <1 | 17.82 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Brunetti, P.; Pichini, S.; Pacifici, R.; Busardò, F.P.; del Rio, A. Herbal Preparations of Medical Cannabis: A Vademecum for Prescribing Doctors. Medicina 2020, 56, 237. https://doi.org/10.3390/medicina56050237
Brunetti P, Pichini S, Pacifici R, Busardò FP, del Rio A. Herbal Preparations of Medical Cannabis: A Vademecum for Prescribing Doctors. Medicina. 2020; 56(5):237. https://doi.org/10.3390/medicina56050237
Chicago/Turabian StyleBrunetti, Pietro, Simona Pichini, Roberta Pacifici, Francesco Paolo Busardò, and Alessandro del Rio. 2020. "Herbal Preparations of Medical Cannabis: A Vademecum for Prescribing Doctors" Medicina 56, no. 5: 237. https://doi.org/10.3390/medicina56050237